Treatment with a pure factor IX concentrate in a patient with moderate hemophilia B undergoing bilateral total hip replacement
- 12 November 1993
- journal article
- case report
- Published by Wiley in Transfusion
- Vol. 33 (11), 936-939
- https://doi.org/10.1046/j.1537-2995.1993.331194082386.x
Abstract
Recently, a pure factor IX concentrate, licensed in Sweden as Immunine, was prepared through ion exchange and hydrophobic chromotography. Virus inactivation included two steps of steam treatment. Reconstituted Immunine could be kept at room temperature for at least 7 days without any substantial loss of activity. A patient with moderate hemophilia B undergoing bilateral total hip replacement was continuously infused with Immunine by use of a pump. There were no bleeding complications or signs of thrombosis, and the operation markedly improved the patient's range of motion and quality of life.Keywords
This publication has 2 references indexed in Scilit:
- Standardization of Factor IX: Standards for "Purified" Factor IX ConcentratesThrombosis and Haemostasis, 1991
- In vitro and in vivo Characterization of Factor VIII PreparationsVox Sanguinis, 1980